Furthermore, the metastatic SS mouse model expressed OSMR at a 22.4-fold increase over the non-metastatic model, suggesting that an OSMR targeted treatment might be more effective against aggressive tumor phenotypes. This evidence concerns the gene OSMR and neoplasm.